Camelot Portfolios LLC cut its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 1.2% during the second quarter, Holdings Channel reports. The fund owned 2,860 shares of the medical research company’s stock after selling 34 shares during the period. Camelot Portfolios LLC’s holdings in Quest Diagnostics were worth $318,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of DGX. YorkBridge Wealth Partners LLC boosted its stake in Quest Diagnostics by 1.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 1,188 shares of the medical research company’s stock worth $127,000 after buying an additional 18 shares in the last quarter. Parallel Advisors LLC boosted its stake in Quest Diagnostics by 16.1% in the first quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock worth $137,000 after buying an additional 177 shares in the last quarter. Advisors Capital Management LLC bought a new stake in Quest Diagnostics during the first quarter worth approximately $164,000. Financial Architects Inc boosted its stake in Quest Diagnostics by 5.6% in the second quarter. Financial Architects Inc now owns 1,666 shares of the medical research company’s stock worth $185,000 after buying an additional 88 shares in the last quarter. Finally, Wagner Bowman Management Corp bought a new stake in Quest Diagnostics during the second quarter worth approximately $200,000. 90.97% of the stock is currently owned by institutional investors.

Shares of Quest Diagnostics Incorporated (NYSE DGX) opened at 106.97 on Monday. The company’s 50 day moving average price is $109.18 and its 200 day moving average price is $102.41. Quest Diagnostics Incorporated has a 52-week low of $79.12 and a 52-week high of $112.96. The stock has a market capitalization of $14.59 billion, a PE ratio of 21.56 and a beta of 0.69.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same period in the previous year, the business earned $1.34 EPS. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities research analysts anticipate that Quest Diagnostics Incorporated will post $5.69 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, July 24th. Investors of record on Monday, July 10th were paid a dividend of $0.45 per share. The ex-dividend date was Thursday, July 6th. This represents a $1.80 annualized dividend and a yield of 1.68%. Quest Diagnostics’s dividend payout ratio (DPR) is 36.29%.

ILLEGAL ACTIVITY NOTICE: “Camelot Portfolios LLC Sells 34 Shares of Quest Diagnostics Incorporated (NYSE:DGX)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/07/camelot-portfolios-llc-sells-34-shares-of-quest-diagnostics-incorporated-nysedgx.html.

A number of equities research analysts have recently commented on the company. UBS AG raised Quest Diagnostics from a “market perform” rating to an “outperform” rating in a research note on Friday, April 21st. Zacks Investment Research cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. BidaskClub cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Piper Jaffray Companies increased their target price on Quest Diagnostics to $107.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 25th. Finally, Bank of America Corporation raised Quest Diagnostics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $111.00 to $118.00 in a research note on Tuesday, July 25th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $110.72.

In other Quest Diagnostics news, SVP Catherine T. Doherty sold 59,762 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $107.55, for a total transaction of $6,427,403.10. Following the sale, the senior vice president now owns 78,582 shares in the company, valued at approximately $8,451,494.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey M. Leiden sold 1,304 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $108.73, for a total value of $141,783.92. Following the sale, the director now owns 6,296 shares in the company, valued at approximately $684,564.08. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.